This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Biomerica, Inc. develops, manufactures, and markets medical diagnostic test kits, primarily using enzyme-linked immunosorbent assay (ELISA) technology. A core component of ELISA development and production is the use of animal-derived antibodies, which are typically harvested from the blood of animals like rabbits, mice, goats, or horses. The company’s product line and receipt of federal grants, such as a $172,890 Qualifying Therapeutic Discovery Project Grant for ELISA development, are fundamentally tied to this industry-standard practice that exploits animals.
While specific details of Biomerica’s animal use protocols are not publicly documented in the provided sources, the company operates within a diagnostic sector where animal testing is an entrenched, non-optional step for bringing products to market. The absence of a publicly available animal welfare policy or commitment to developing non-animal derived alternatives places the company’s operations squarely within the commercial exploitation of animals.
Biomerica, Inc. develops, manufactures, and markets medical diagnostic test kits and devices. The company’s product development and regulatory compliance for these biomedical products inherently involves animal testing, a standard but required practice for securing FDA and other global health authority approvals. As a biomedical technology company, animal data forms a foundational part of its research and validation processes.
While specific violation records for Biomerica are not detailed in the provided evidence, the company operates within a sector where animal testing is a regulatory necessity for product submissions, such as the referenced FDA 510(k) application K992799. The broader industry context, as highlighted by reports from Cruelty Free Investors and audits of U.S. labs, underscores the systemic animal use and documented welfare violations prevalent in biomedical research and diagnostic development.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.